Literature DB >> 8617331

Plasmodium yoelii: the role of the individual epidermal growth factor-like domains of the merozoite surface protein-1 in protection from malaria.

P A Calvo1, T M Daly, C A Long.   

Abstract

The merozoite surface protein-1 (MSP-1) is a leading candidate for a vaccine targeted at the erythrocytic stages of plasmodial parasite development. Recently, there has been increasing interest in this polypeptide, particularly in the carboxyl-terminal EGF-like domains. We have previously shown that this region from Plasmodium yoelii, when expressed in native configuration, could immunize mice against an otherwise lethal challenge infection. In this model system, protection appears to be predominantly mediated by antibodies. In all rodent immunization studies to date, however, the immunogen has contained both of the postulated EGF-like domains. We report here on the efficacy of immunization with the individual EGF-like domains from P. yoelii in elicitation of a protective host response. Although all animals developed some level of antibody in response to the various immunogens, only those animals immunized with both EGF-like domains produced antibodies which could recognize the native MSP-1 molecule. Antibodies generated against the individual EGF-like domains did cross-react with the double EGF-like domain structure, suggesting that the immunogens had retained elements of native configuration. In addition, only those animals which generated antibodies capable of recognizing native MSP-1 showed any level of protection from challenge infection. These results suggest that determinants unique to the double EGF-like domain structure may be necessary for the generation of antibodies specific for the native configuration of MSP-1 and that these antibodies may play a significant role in protection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617331     DOI: 10.1006/expr.1996.0007

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.

Authors:  L Wang; C G Black; V M Marshall; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Authors:  Zhi-Hong Zhang; Pei-Hong Jiang; Ning-Jun Li; Mi Shi; Weida Huang
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.

Authors:  L Kedzierski; C G Black; R L Coppel
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum.

Authors:  C G Black; L Wang; A R Hibbs; E Werner; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant.

Authors:  J B De Souza; I T Ling; S A Ogun; A A Holder; J H Playfair
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

6.  Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.

Authors:  L M Spencer Valero; S A Ogun; S L Fleck; I T Ling; T J Scott-Finnigan; M J Blackman; A A Holder
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

7.  Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.

Authors:  L Rénia; I T Ling; M Marussig; F Miltgen; A A Holder; D Mazier
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.